|
18 Apr 2025 |
Aarti Industries
|
Consensus Share Price Target
|
399.75 |
483.40 |
- |
20.93 |
hold
|
|
|
|
|
10 May 2023
|
Aarti Industries
|
Axis Direct
|
399.75
|
550.00
|
507.25
(-21.19%)
|
Target met |
Hold
|
|
|
Recommendation With the stock witnessing significant correction, we see a potential upside of 9% from the CMP of 505/share. With the stock lacking a trigger for the upside, we maintain a HOLD rating on the stock.
|
|
10 Apr 2023
|
Aarti Industries
|
Geojit BNP Paribas
|
399.75
|
624.00
|
537.00
(-25.56%)
|
Target met |
Buy
|
|
|
|
|
07 Feb 2023
|
Aarti Industries
|
Prabhudas Lilladhar
|
399.75
|
660.00
|
534.95
(-25.27%)
|
Target met |
Accumulate
|
|
|
|
|
17 Nov 2022
|
Aarti Industries
|
KRChoksey
|
399.75
|
841.00
|
676.70
(-40.93%)
|
|
Buy
|
|
|
In Q2FY23, Aarti’s revenue grew 34.2% YoY/4.6% QoQ to INR 16,850 mn. During the quarter, the demerger of Pharma Business from Aarti Industries into its wholly owned subsidiary Aarti Pharmalabs Limited was approved by National Company Law Tribunal (NCLT), on September 21, 2022
|
|
16 Nov 2022
|
Aarti Industries
|
Prabhudas Lilladhar
|
399.75
|
775.00
|
655.60
(-39.03%)
|
|
Accumulate
|
|
|
|
|
30 Sep 2022
|
Aarti Industries
|
CD Equisearch
|
399.75
|
612.00
|
771.50
(-48.19%)
|
Target met |
Sell
|
|
|
|
|
17 Aug 2022
|
Aarti Industries
|
SBI Securities
|
399.75
|
1005.00
|
875.30
(-54.33%)
|
|
Buy
|
|
|
|
|
12 Aug 2022
|
Aarti Industries
|
KRChoksey
|
399.75
|
1094.00
|
818.35
(-51.15%)
|
|
Buy
|
|
|
In Q1FY23, Aarti’s revenue grew 49.8% YoY/12.3% QoQ to INR 19,720 mn, beating our estimate by 9.3%
|
|
12 Aug 2022
|
Aarti Industries
|
ICICI Direct
|
399.75
|
885.00
|
818.35
(-51.15%)
|
Target met |
Hold
|
|
|
|
|
12 Aug 2022
|
Aarti Industries
|
Axis Direct
|
399.75
|
875.00
|
818.35
(-51.15%)
|
Target met |
Hold
|
|
|
We maintain our estimates and TP of Rs 875/share, valuing the company at 20x its FY24E EPS and change our recommendation from BUY to Hold. The TP implies an upside of 7.3% from the CMP.
|